- Home
- DMRC vs BDTX Comparison
DMRC vs BDTX Comparison
Compare DMRC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRC | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 116.8M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DMRC | BDTX |
|---|---|---|
| Price | $4.69 | $2.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $10.20 |
| AVG Volume (30 Days) | 272.0K | ★ 581.5K |
| Earning Date | 03-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.58 | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $25,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.62 |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $1.20 |
| 52 Week High | $14.64 | $4.94 |
Technical Indicators
Market Signals| Indicator | DMRC | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 43.81 |
| Support Level | $4.07 | $1.93 |
| Resistance Level | $7.10 | $2.30 |
| Average True Range (ATR) | 0.64 | 0.11 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 12.64 | 36.54 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.